Mårten Falkenberg/ Vascular News
Aug 31, 2025, 07:12
Late-Breaking SWEDEPAD Trial Finds No Benefit of Drug-Coated Balloons and Stents, Raises Safety Concerns
Vascular News shared an important post on LinkedIn:
“BREAKING NEWS: Drug-coated balloons and stents were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in the SWEDEPAD 1 and 2 trials. In addition, higher five-year mortality with drug-coated devices in patients with intermittent claudication was noted, leading researchers to stress that the safety of paclitaxel-coated devices is an “ongoing discussion”.
These late-breaking findings were presented today at the European Society of Cardiology (ESC) 2025 congress (29 August–1 September, Madrid, Spain) and simultaneously published in The Lancet Group.”
Read more here.
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 15:41Sam Tsimikas on Lp(a) HORIZON Topline Results – What Missed Endpoints Mean for Cardiovascular Risk
-
Sep 5, 2026, 15:32Stefano Garzon: SELUTION DeNovo HBR – Weren’t HBR Patients Supposed to Bleed More with DES?
-
Sep 5, 2026, 15:24Mayer Hany: Recombinant Activated FVII in Spontaneous Intracerebral Hemorrhage
-
Sep 5, 2026, 15:09Consuela A. Albright: Clinical Advocacy in Sickle Cell Disease
-
Sep 5, 2026, 15:00Brandon Buck: Human Cell-Free DNA as a Diagnostic Tool for Aging and Rare Blood Disorders
-
Sep 5, 2026, 14:57Archil Jaliashvili: What if Normal Hb and SpO₂ Still Do not Mean Adequate Tissue Oxygenation?
-
Sep 5, 2026, 14:52Evaluating Inhibitor Risk Following Factor Product Switches – Results from ATHN 2
-
Sep 5, 2026, 14:50Sandrine Oziel-Taieb: Hematological Toxicity Management During Lu-Dotatate
-
Sep 5, 2026, 14:43Nandini Pethe: How Digital Logs Help Recognize Pediatric von Willebrand Disease